Proton pump inhibitors (PPIs) are known as a class of pharmaceutical agents that target
H+/K+-ATPase, which is located in gastric parietal cells. PPIs are widely used in the …

Proton pump inhibitors (PPIs) have become some of the most frequently prescribed
medications for treatment of adults and children. Their effectiveness for treatment of peptic …

Proton pump inhibitors (PPIs) are used widely for the treatment of acid-related disorders.
Despite their excellent efficacy and tolerance, the pharmacodynamics and pharmacokinetics …

AIM: To evaluate the efficacy, safety and influential factors of proton pump inhibitor (PPI)
treatment for non-erosive reflux disease (NERD). METHODS: PubMed, MEDLINE, EMBASE …

The interaction between ilaprazole and bovine serum albumin (BSA) has been investigated
in the absence and presence of four popular flavonoids with different C-ring structures …

Introduction: Approximately 20% of the Western population is affected by gastro-esophageal
reflux disease (GERD). To date, proton pump inhibitors (PPIs) represent the mainstay of …

It is well known that the CYP2C19 genetic polymorphism influences the pharmacokinetics
and pharmacodynamics of proton pump inhibitors (PPIs), but no report has addressed the …

Objective: The new proton pump inhibitor (PPI), ilaprazole performed better at the dose of 10
mg/d relative to 5 or 20 mg/d in a previous phase II trial. A larger phase III trial was carried …

Proton-pump inhibitors (PPIs) are the most administered first-line treatment for eosinophilic
esophagitis (EoE). However, only around half of EoE patients respond histologically to a …

Ilaprazole is a new proton pump inhibitor, designed for treatment of gastric ulcers, and
developed by Il-Yang Pharmaceutical Co (Seoul, Korea). It is extensively metabolised to the …